Smart Blood Analytics Swiss has obtained European Medical Device Regulation (EU-MDR) for its SBAS Software. This makes it the first artificial intelligence (AI) blood test interpretation medical device to be recognized in Europe. As a company press release explains, it is now one of just 10 AI medical device companies to hold this prestigious certification, which guarantees that a medical device has been rigorously tested for safety and quality and complies with EU requirements.
According to the press release, SBAS Software not only improves speed and accuracy in interpreting blood test results but also gives medical professionals valuable insights into the health of their patients. Smart Blood Analytics Swiss, which was founded in 2016, is focused on improving differential diagnosis. It uses machine learning algorithms to develop various AI models that predict the most probable diagnoses, based solely on an individual’s blood test results.
“Receiving EU-MDR certification is a testament to our dedication to innovation and patient well-being,” says CEO and founder Dr Marko Notar, adding that it is “a recognition of our commitment to delivering the highest quality solutions to healthcare professionals and, ultimately, to patients worldwide.” ce/mm
Related documents
Learn more about the benefits of doing business in the Greater Zurich Area.
Erfahren Sie, welche Standortvorteile Greater Zurich für europäische Expansionen bietet.
Learn from industry leaders about talent, tax, and intellectual property.
The PDF takes a look at the biotech industry’s developments and innovation in the region.
The PDF provides key figures and information about Greater Zurich as a leader in AI.
Related news
Contact us
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?
info@greaterzuricharea.com